Lone Star Bio
Filter News
Found 18,325 articles
-
Legacy Medical Consultants Announces Reeva FT™, a Full-Thickness Allograft for Wound Covering and Protection During Treatment
4/19/2024
Legacy Medical Consultants (LMC) announces its newest product portfolio addition with the recent Q code approval for Reeva FT™, a terminally sterilized, full-thickness, dual-layered amnion/chorion allograft designed for covering and protection during advanced wound treatment.
-
Sensi.AI Appoints Renowned Home Care Advocate, Bob Roth, to its Advisory Board Combining Data-Driven Insights with Decades of Home Care Expertise to Revolutionize Aging in Place
4/19/2024
Sensi.AI , a leader in AI-native, data, and analytics in senior care, today announced the appointment of in-home care leader Bob Roth to its Advisory Board.
-
Form Bio Establishes Scientific Advisory Board, Comprised of Renowned Experts in Cell and Gene Therapy, for Advancing AI-Driven Therapies
4/18/2024
Form Bio today announced the creation of a new Scientific Advisory Board (SAB).
-
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
4/18/2024
Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to Annamycin for the treatment of AML.
-
Texas Biomed researching vaccines and treatments for highly pathogenic avian influenza
4/18/2024
Researchers at Texas Biomedical Research Institute (Texas Biomed) are studying potential vaccines, antivirals and antibodies against highly pathogenic avian influenza, including H5N1 strains that closely mirror the one recently detected in cows, chickens and one person in Texas.
-
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4/18/2024
Bio-Path Holdings, Inc. announced that it has entered into a definitive agreement with certain institutional investors for the issuance and sale of 375,000 shares of its common stock at a purchase price per share of $3.225 in a registered direct offering priced at-the-market under Nasdaq rules.
-
Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients
4/18/2024
Bio-Path Holdings, Inc. today announced completion of the second dose cohort of the dose escalation portion of its Phase 1/1b clinical trial of BP1002 evaluating the ability of BP1002 to treat refractory/relapsed acute myeloid leukemia.
-
Lexicon Pharmaceuticals to Host 2024 Investor Day
4/18/2024
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that senior company executives will be joined by leading physicians at the Lexicon 2024 Investor Day on April 22, 2024.
-
Renibus Therapeutics Announces Oral Presentation on RBT-1 at the European Association for Cardio-Thoracic Surgery (EACTS) 2nd Innovation Summit
4/18/2024
Renibus Therapeutics today announced an oral presentation on RBT-1 at the prestigious, invitation only, European Association for Cardio-Thoracic Surgery (EACTS) 2 nd Innovation Summit, taking place in Paris, France, April 18-20, 2024.
-
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
4/18/2024
Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that President and Chief Medical Officer Dr. Fred Grossman, D.O., FAPA will participate in the 3rd Annual ALS Drug Development Summit being held May 21 – 23 at the Hyatt Regency in Boston.
-
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
4/18/2024
Lumos Pharma, Inc. (NASDAQ:LUMO) announced today that abstracts reviewing data from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials will be presented at several upcoming medical meetings in the US and Europe.
-
Nanoscope Therapeutics to Present at the World Orphan Drug Congress 2024
4/17/2024
Nanoscope Therapeutics Inc. today announced that Sulagna Bhattacharya , Chief Executive Officer and Samarendra Mohanty, PhD, President and Chief Scientific Officer will present and participate in a panel discussion at the World Orphan Drug Congress 2024, taking place from April 23-25, 2024 in Boston, Massachusetts.
-
Babson Diagnostics Develops Hand-Warming Device to Support Collection of High-Quality Capillary Blood Samples
4/16/2024
Babson Diagnostics today announced the newest innovation in its BetterWay™ blood testing ecosystem has completed validation testing.
-
Autonomix Announces Issuance of U.S. Patent Covering Proprietary Catheter-Based Technology for the Treatment of Cancer Related Pain
4/16/2024
Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”) today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. patent 10,143,419 ('419 patent) entitled “Systems and Methods for Treating Cancer and/or Augmenting Organ Function.”
-
Xstim, Inc. Receives FDA Approval for Xstim™ Spine Fusion Stimulator.
4/16/2024
Xstim, Inc., a pioneering developer and manufacturer of cutting-edge bone growth stimulation systems, is thrilled to announce its recent Premarket Application approval from the U.S. Food and Drug Administration for Xstim™ Spine Fusion Stimulator.
-
QSAM Announces Reverse Stock Split Ratio Ahead of Merger
4/16/2024
QSAM Biosciences, Inc. previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of QSAM’s common stock, par value $0.0001 per share, at a ratio in the range of 1:1000 to 1:2000, prior to the closing of the merger between the Company and Telix Pharmaceuticals Limited pursuant to which Telix will acquire QSAM.
-
Nacuity Pharmaceuticals Expands Board of Directors with Appointment of Dr. Emmett Cunningham, Jr.
4/16/2024
Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel treatments for retinitis pigmentosa, cataract, and other diseases caused by oxidative stress, announced the appointment of Emmett T. Cunningham, Jr., M.D., Ph.D., MPH, to its board of directors.
-
Orthofix Names Andres Cedron as New Chief Legal Officer
4/16/2024
Orthofix Medical Inc . (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that Andres Cedron has joined the company as Chief Legal Officer.
-
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
4/16/2024
CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), and The University of Texas MD Anderson Cancer Center today announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.
-
Redemption Date Announced for Warrants - April 15, 2024
4/15/2024
Cassava Sciences, Inc. announced that Monday, May 6, 2024 is the last and final day to exercise the warrants that were previously distributed to its shareholders on January 3, 2024.